Member Info for daveycaferacer

$18.99 on nasdaq today , someone is buying

I was particularly buoyed by our CEO's comments about Lilly and their right to exercise rights in ROW in the next few months. Also we are expecting further milestone payments this year. But my biggest surprise was how the Commerical division has performed - Consolidated sales of $180.9m against guidance of $155.0m – $165.0m

The American have woken up at last!

Another set of fantastic results and progress, CP consolidated revenues and net income stand out particularly I look forward to today's calls and digesting the announcement in full!

Mark Slater's newly updated Fundsheet shows the following as a percentage of the Growth Fund Hutchison China Meditech - 5.85% Speaking of growth, the fund will obviously continue its First Quartile position as he loves Chi-Med!

Thankyou Azurite, IC seem to be a fan of HCM FY16 Results Monday!!

If the share price continues to rise Mr Slater may have to make a partial disposal to avoid breaking his won fund rules, a nice problem to have however.

Indeed, I realised that seconds after posting, it must have been the excitement! This is his third article in the last few years, I wonder if he is a holder.........

Here's the article http://www.standard.co.uk/business/anthony-hilton-patience-pays-as-chimed-seeks-cancer-cure-a3483676.html

Another comprehensive full page article in the Business section of todays ES by a big fan of Chi-Med, Anthony Bolton. For those not in London you can probably view the article on the ES website ;o-) He has written a couple of comprehensive articles before and is very enthusiastic. In particular i lime his optimism about our valuation! "For a Company like Chi-Med with potential revenues of at least $1 billion, that could imply a valuation of $20 billion" Whilst I think his P/S of 20 is a bit on the high side it is not unprecedented, you only have to look at Genmab to see its possible.

2017: Defining year for Hutchison Valuation: $2.4bn ($20.1/ADS) Our SOTP valuation remains unchanged at $2.4bn ($20.1/ADS). IP is valued at $1,789m and placing the commercial platform’s (CP) 2016e share of net profit on a 22.5x rating gives $657m ($5.4/ADS). Adding net cash at end June 2016 and netting out unallocated costs results in a value of $2.4bn. Approval(s), clinical data and/or deals should increase our risk-adjusted valuation.

I take it all back, the U.S. market is defying all odds in terms of price action and volume!

The trend continues - the opening of the US market drags the UK back down again

A whopping 0.85% rise on NASDAQ

you're right! $32bn mcap and no revs and no profit.........yet But then again I invested in Facebook and sold within a few months, if I had been patient I'd have made a lot of money Speaking of being patient, and making a lot of money both of those apply here IMO. Those prepared to build a position and be patient will be very well rewarded. Looking forward to the next announcement which may include:- Savolitinib Phase III in c-Met-driven PRCC. - wil include large up-front Milestone payment Epitinib Phase II/III in first-line patients with EGFR-mutant NSCLC with brain metastasis. Savolitinib Phase III in combination with Tagrisso® (osimertinib) in second-line NSCLC (T790M-/c-Met+). $40m dividend due from Commercial JV by end June Fruquintinib NDA in China by mid 2017

Huge volume compared to usual, already about 8x normal daily volumes

It seems we can always trust the NASDAQ market to bring us down. It did so with the IPO and it seems to do so on very material news too.

Yes, I meant the Results are on the 13th, the AGM will be at the end of April I attend every year, my Broker provides a letter of Representation. I can't vote at the meeting as my holdings are all on a nominee basis but I have no interest in voting, CK Husthison holds the majority and always does the right thing anyway ;o-)

Someone is keen on buying (in addition to me that is, I am always buying)

miti, you mean CRC? I only have the data Edison produced in their last note:- $106m peak sales China (HCM tiered royalties (15-20%) $632m peak sales ROW (HCM tiered royalties circa 11%) + up to $300m milestone payments across all Fruquintinib indications Let's hope NASDAQ reacts accordingly bearing in mind the ADR's are almost unbelievably below issue price!